肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Biotechnol Appl Bioc：合肥研究院在miRNA快速检测方面取得进展

2018-12-27 佚名 合肥研究院

miRNA肿瘤检测诊断标志物
关注

近期，中国科学院合肥物质科学研究院医学物理与技术中心生物电子技术研究室在miRNA快速检测方面取得新进展。课题组成员基于等温滚环扩增（RCA）技术，设计了一种新型的便携式miRNA快速检测系统，可以方便、快速检测血液及组织中的miRNA。相关研究成果已经在线发表在Biotechnology and Applied Biochemistry上

近期，中国科学院合肥物质科学研究院医学物理与技术中心生物电子技术研究室在miRNA快速检测方面取得新进展。课题组成员基于等温滚环扩增（RCA）技术，设计了一种新型的便携式miRNA快速检测系统，可以方便、快速检测血液及组织中的miRNA。相关研究成果已经在线发表在Biotechnology and Applied Biochemistry上。

miRNA是人体的一种重要RNA，研究表明它特异性强，可以作为很多疾病的诊断标志物。生物电子技术研究室研究人员基于等温滚环扩增（RCA）技术，采用光电检测方法检测特异性标志物受激发出的荧光强度，设计了一种便携式miRNA快速检测系统，解决了现有miRNA检测方法系统复杂、操作繁琐、检测时间长的缺点。miR-183是miRNA的一种，其异常表达可以作为肝癌疾病的标志。相关研究人员利用设计的检测系统检测了肝癌患者和非肝癌患者血液及肝组织中的miR-183，结果表明系统可以明显地区分肝癌患者和非肝癌患者。

便携式miRNA快速检测系统能对样品进行实时现场分析，在临床应用和个体医疗方面有很大的应用前景。


图1 便携式miRNA快速检测仪


图2 正常肝组织和肝癌组织中miRNA-183的检测结果


图3 非肝癌患者和肝癌患者血液中miRNA-183的检测结果

原始出处：Zhanying Zhang, Yanfei Wang, Yanlei Li, et al. Portable fluorescence‐based microRNA detection system based on isothermal signal amplification technology. Biotechnol Appl Bioc. 12 October 2018

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1927700, encodeId=e0d6192e700bd, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sun Sep 01 12:41:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652312, encodeId=b8801652312f4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Sep 19 14:41:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918447, encodeId=b454191844ef0, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 25 12:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930671, encodeId=2b7119306e112, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Dec 09 10:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312361, encodeId=30b3131236139, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Dec 29 05:41:00 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2019-09-01 cathymary

    #Biotech#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1927700, encodeId=e0d6192e700bd, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sun Sep 01 12:41:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652312, encodeId=b8801652312f4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Sep 19 14:41:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918447, encodeId=b454191844ef0, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 25 12:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930671, encodeId=2b7119306e112, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Dec 09 10:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312361, encodeId=30b3131236139, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Dec 29 05:41:00 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2019-09-19 shock_melon

    #TEC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1927700, encodeId=e0d6192e700bd, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sun Sep 01 12:41:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652312, encodeId=b8801652312f4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Sep 19 14:41:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918447, encodeId=b454191844ef0, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 25 12:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930671, encodeId=2b7119306e112, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Dec 09 10:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312361, encodeId=30b3131236139, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Dec 29 05:41:00 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2019-01-25 sunylz

    #Bio#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1927700, encodeId=e0d6192e700bd, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sun Sep 01 12:41:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652312, encodeId=b8801652312f4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Sep 19 14:41:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918447, encodeId=b454191844ef0, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 25 12:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930671, encodeId=2b7119306e112, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Dec 09 10:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312361, encodeId=30b3131236139, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Dec 29 05:41:00 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2019-12-09 smallant2002

    #miR#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1927700, encodeId=e0d6192e700bd, content=<a href='/topic/show?id=a59234e3b4' target=_blank style='color:#2F92EE;'>#Biotech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3473, encryptionId=a59234e3b4, topicName=Biotech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Sun Sep 01 12:41:00 CST 2019, time=2019-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652312, encodeId=b8801652312f4, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu Sep 19 14:41:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918447, encodeId=b454191844ef0, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jan 25 12:41:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930671, encodeId=2b7119306e112, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Dec 09 10:41:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312361, encodeId=30b3131236139, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Dec 29 05:41:00 CST 2018, time=2018-12-29, status=1, ipAttribution=)]
    2018-12-29 Homburg

    #miRNA#

    0

相关资讯

盘点：miRNA 在眼科中研究进展

Exp Eye Res：MicroRNA-218-5p通过PI3K / Akt / mTOR信号通路靶向EGFR抑制翼状胬肉上皮细胞的迁移和增殖 天津市眼科医院的Han S等人近日在Exp Eye Res杂志上发表了一项重要工作。翼状胬肉是一种常见的眼表疾病，可引起各种眼表症状。微RNA在各种眼部疾病的发展中起重要作用。然而，对于microRNA在翼状胬肉中的发病机制中的作用很少研究。他

Oncogene：miR-96和RARγ信号途径能够调控雄激素信号和前列腺癌恶化

在前列腺癌（PCa）中，视黄酸受体γ（NR1B3/RARG编码RARγ）的表达通常是减少的。因此，有研究人员探究了RARγ表达减少后的细胞学和基因调控结果，并且确定了RARγ调控机制。在非恶性（RWPE-1和HPr1-AR）和恶性（LNCaP）前列腺模型中，RARG shRNA方法能够减少RARγ水平；且RARγ水平的减少，而不是添加外源维甲酸，能够对前列腺细胞的存活和基因的表达产生最大的影响。C

Biomaterials：肿瘤微环境响应磁共振纳米诊疗剂研究取得进展

近期，中国科学院合肥物质科学研究院技术生物与农业工程研究所研究员吴正岩课题组与上海交通大学医学院教授邹多宏团队合作，利用磁性氧化铁与硅酸锰纳米复合物制备出一种对肿瘤微环境响应的纳米磁共振造影剂和药物递送系统，相关工作已被生物材料期刊Biomaterials 接收发表。

Gastroenterology：MiRNA检测在巴雷特食管诊断中的应用

研究发现，巴雷特食管患者存在特异的MiRNA过表达现象，是有效的巴雷特食管诊断方法，其中MIR194表达增加可能通过表观遗传机制参与疾病的发生

Cell Death Dis：研究揭示miRNA在调节脂肪组织干细胞修复糖尿病伤口中的作用及机制

晚期糖基化终产物/晚期糖基化终产物受体（AGEs/AGER）相互作用触发活性氧（ROS）生成，激活下游信号通路，并诱导内皮祖细胞凋亡。许多研究揭示microRNA（miRNA）参与调节细胞内ROS产生和细胞凋亡。然而，很少有研究探讨miRNA在调节脂肪组织干细胞（ADSCs）修复糖尿病伤口中的作用，且相关的细胞机制尚不清楚。在这项研究中，将ADSCs暴露于AGEs，然后将AGER的siRNA转染到

Sci Rep：前列腺癌的4种MicroRNA诊断分析

全球每年诊断的前列腺癌男性数目高于100万，然而目前的诊断方式仍旧对明显的癌症的鉴定存在不足，并且更加可靠的早期生物诊断标记在前列腺癌患者临床治疗的改善方面也是必需的。MicroRNA（miRNAs）能够调控重要的细胞学过程/通路，并能导致癌症且在体液中稳定存在。最近，有研究人员在血浆中分析了372个癌症相关的miRNAs，分析的时间在治疗开始前（大约60%的患者）和治疗开始后及治疗期间（大约40